Skip to main content
Shahky Early Access Program Now Available—Sign-up to Learn More
Shahky Early Access Program Now Available—Sign-up to Learn More

For Pharma

The industry’s first exosome-based diagnostics are designed to overcome the limitations of currently available molecular diagnostics and deliver on the true promise of personalized healthcare. We are leaders in collaborating with the biopharmaceutical industry, helping companies leverage exosome-based science to enhance the R&D process, from biomarker discovery through validation, and the development of sophisticated companion diagnostics to maximize the potential of targeted therapies.

Biomarker strategies are incorporated into virtually every R&D process, starting with the earliest stages of clinical development. Sourcing tissue to identify biomarkers can lead to delays in clinical trial recruitment and complicate clinical study design and implementation. By providing biopharma companies with biofluid-based solutions for clinical trials, we can overcome these tissue-related obstacles.

Utilizing our best-in-class technology, we can assess biomarker status without using historical tissue or requiring a biopsy. This offers biopharma companies several key advantages including:

  • Access to a virtually unlimited supply of molecular information via biofluids
  • Enhanced freedom with clinical trial design
  • Accelerated clinical trial enrollment
  • Shortened study duration
  • Reduced overall clinical study costs
  • Potential increased time on patent life

For more information, please contact

Available in 2016: Solid Tumor Mutation Detection Panel

Our plasma-based solid tumor mutation detection panel covers 26 of the most important genes and 1000 associated mutations in the most significant pathways of cancer, including EGFR/MAPK and PI3K. Using a simple blood test, the panel utilizes our unique exosome-based technology platform to simultaneously isolate and analyze exosomal RNA (exoRNA) and cell-free DNA (cfDNA), two biologically distinct sources of circulating nucleic acids. Combining exoRNA and cfDNA in a single step enables the panel to achieve ultra-sensitive detection of rare cancer mutations. Learn more.